- Home
- AQST
as 04-18-2025 1:31pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 254.1M | IPO Year: | 2018 |
| Target Price: | $11.17 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.20 - $5.80 | Next Earning Date: | 05-06-2025 |
| Revenue: | $57,561,000 | Revenue Growth: | 13.79% |
| Revenue Growth (this year): | -12.11% | Revenue Growth (next year): | 39.51% |
Latest Aquestive Therapeutics Inc. News
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
GlobeNewswire
10 days ago
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
GlobeNewswire
18 days ago
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
Simply Wall St.
a month ago
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
GuruFocus.com
a month ago
Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
MT Newswires
a month ago
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
MT Newswires
a month ago
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued
Zacks
a month ago
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
Compare AQST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.